logo-loader
viewBiocept Inc

Biocept to provide coronavirus test kits, will cover out-of-network patients for liquid biopsy tests

Biocept Inc (NASDAQ:BIOC) CEO Mike Nall and CFO Tim Kennedy tell Proactive the California-based firm has solved supply chain problems of obtaining 10,000 testing kits to provide coronavirus test to patients.

Separately, Nall says the firm has agreed to a managed care provider agreement with Medical Cost Containment Professionals LLC (MCCP) to process out-of-network insurance claims for its Target Selector liquid biopsy testing.

Quick facts: Biocept Inc

Price: 0.7145 USD

NASDAQ:BIOC
Market: NASDAQ
Market Cap: $93.62 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Biocept reveals double-digit revenue jump and new Target Selector molecular...

Biocept Inc (NASDAQ:BIOC) CEO Mike Nall tells Proactive how the California-based company saw revenue jump by double-digits in its fiscal first quarter despite headwinds from the coronavirus pandemic. What's more, Nall says the developer of liquid biopsy tests has released a new Target...

on 05/26/2020

2 min read